vTv Therapeutics (NASDAQ: VTVT) is a late-stage biopharmaceutical company. It focuses on developing treatments for metabolic diseases. Its main project is cadisegliatin, a new oral therapy being tested for type 1 diabetes. Before the market opened, vTv Therapeutics reported strong quarterly results. The company announced an earnings per share of $1.65. This figure greatly surpassed the analyst consensus estimate of just $0.21 per share. The company's current ratio is 14.36. This metric suggests a strong abi ...